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it is a direct measure of treatment effect on tumour burden andmeasures only the
effect of the study drug. PFS has also been accepted by regulatory bodies as a
measure of the efficacy of cancer treatments. CONCLUSIONS: OS is generally re-
garded as the preferable endpoint (from a payer’s perspective) for demonstrating
clinical efficacy in NSCLC. There are challenges, however, with demonstrating OS
benefit of new therapies for NSCLC. PFS data may be more appropriate for use in
certain situations, especially those in which subsequent lines of therapy exist.
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OBJECTIVES: The objective of the study was to propose an alternative indirect
comparison method and compare it to the standard method. METHODS: In the
absence of head-to-head trials, the standard method for estimating indirect rela-
tive effectiveness is to obtain an indirect hazard ratio (HR) estimate using the two
HRs from the comparator trials against a common 3rd one. This method, however,
is only valid if the assumption of proportional hazard (PH) holds. We proposed an
alternative indirect comparison method that does not depend on the PH assump-
tion, which consists of calculating the absolute difference between treatment arms
at each two-week period in drug B trial and applying this difference to the common
comparator in drug A trial to generate the adjusted curve for drug B. This was done
for Progression free Survival (PFS) and Overall Survival (OS) from parametric esti-
mates throughout the observed and extrapolated periods. Trial data for cetuximab
and panitumumab in 1st line treatment of wild-type KRAS metastatic colorectal
cancerwas used to examine the PH assumption and compared the twomethods for
estimating the relative treatment effect between the two agents. RESULTS: The
functional form for the PFS and OS distributions was found to be different for
panitumumab versus cetuximab (Weibull shape parameter value for: PFS1.616
versus 1.761; OS1.314 versus 1.336, respectively). Thus, the PH assumption was
violated. Panitumumab trial was set as the reference (the estimated mean PFS
0.917 years and mean OS2.469). Using the standard method and our proposed
method, the indirectly estimated PFS and OS for cetuximab were: mean PFS 0.846
vs 0.920 years; mean OS 2.393 versus 2.312 years, respectively. CONCLUSIONS:
The standard methodology for indirect comparison allows easy execution. How-
ever, if the PH assumption is violated, alternative methods, such as the one pro-
posed in this study, can be considered.
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OBJECTIVES: The objective of this study was to develop a unique linked Medicare-
Medicaid-WV Cancer Registry (WVCR) de-identified dataset to determine health
care utilization, costs and overall burden of breast, colorectal, lung, and prostate
cancers diagnosed in persons  65 years of age who live in WV and to compare
themwith national estimates.METHODS: The data linkagewas performed in three
phases, following process as originally described by Potosky (1993) and adapted by
Bradley (2007) and Koroukian (2008). In phase one, a list of individual’s65 years of
age with incident diagnosis of any cancer between January 1, 2002 and December
31, 2007 was extracted from WVCR data. The SSN, Sex, and Date of Birth of these
individuals were sent to CMS to create a crosswalk file for these individuals to
include with purchased WV Medicare data. In phase two, Medicare data were
linked with WVCR data using the crosswalk file provided by CMS. In phase three,
WVCR data were linked with Medicaid enrollment file data using personal identi-
fiers. After the linkages, all identifiers were removed to create a de-identified re-
search data set. RESULTS: In phase one, we identified 42,288 individuals’65 years
of age with incident diagnosis of any cancer from 2002 to 2007 in the WVCR data.
When linked with Medicare data in the second phase, 41,575 (98.3 %) individuals
were matched. In phase three, WVCR data were matched with Medicaid enroll-
ment data for 5790 (13.7%) individuals using SSN, First Name, and Last Name; for
5860 (13.9%) individuals using SSN, Last Name, Month of Birth, and Sex; and, for
5747 (13.6%) individuals using SSN, First Name, Month of Birth, and Sex.
CONCLUSIONS: Non-participant states in SEER-Medicare can build a powerful
linked Medicare-Medicaid-Cancer Registry dataset to identify and target cancer
disparities to improve outcomes in their elderly and dual-eligible citizens.
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OBJECTIVES: Electronic medical records (EMRs) are used increasingly for research.
Our objectives were a) to understand the utility of an EMR oncology database com-
pared with SEER cancer registry data and Medicare and commercial claims data-
bases and b) to identify areas for improvement in data collection, analysis, and
interpretation in clinical oncology, epidemiology, and comparative effectiveness
research. METHODS: Demographic, clinical, and treatment characteristics in the
four databases were compared using six tumor types: breast, lung/bronchus, head/
neck, colorectum, prostate, and NHL. Data imputation was performed using the
hot-deckmethod; patient characteristics were compared using Cohen’s effect size.
We described patient and clinic inclusion criteria, treatment definitions, and pur-
poses of each database to enable comparisons. RESULTS: Sex and 10-year age
distributions for each tumor type were similar across datasets. The EMR oncology
database had a large proportion of missing data for stage (70%) and race (40%),
which were replaced with imputed values. There were several differences in racial
composition (15%) and ambulatory chemotherapy treatment (30%), andmodest
(10%), differences in distribution of tumor type likely due to differences in geo-
graphic distribution of included patients and clinics. Overall, Cohen’s effects size
analyses indicated small to medium differences (w0.3) in patient characteristics
across databases. Patients in the EMRdatabaseweremore likely to receive biologics
and less likely to receive hormones compared to those in the reference databases,
with the largest differences (40%) observed in prostate cancer patients, who are
usually seen first or primarily by urologists. CONCLUSIONS: Several factors must
be consideredwhen using EMRs for oncology research purposeswith a target of the
US cancer population, particularly when evaluating treatment patterns. Important
factors include evaluation of stage, geography, race, andmedical facilities’ special-
ization. EMR database utility might be enhanced through imputation, addition of
specific physician notes (e.g., stage) and linkage to other data sources.
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OBJECTIVES: To create an overview that makes researchers aware of the available
database linkages in Northern America and Europe which facilitate pharmacoepi-
demiologic studies in cancer patients.METHODS: In addition to our own database,
i.e. the Eindhoven Cancer Registry (ECR) linked to the PHARMO RLS, we considered
database linkages between a population-based cancer registry, that provides de-
tailed tumor information of incident cancer cases, and an administrative health-
care database, that at least contains information on drug use and offers a longitu-
dinal perspective on health care utilization before, during and after cancer
diagnosis. Eligible database linkages should have been used in multiple published
articles in English language included in Pubmed. The Cancer Research Network
(CRN) in the United States was excluded from this review, as an overview of the
linked databases participating in the CRN is already provided elsewhere. Research-
ers who hadworkedwith the data resources included in our reviewwere contacted
for additional information and verification of the data presented in the overview.
RESULTS: Ten database linkages met the inclusion criteria: the SEER-Medicare,
cancer registry data linked to Medicaid, the British Columbia Cancer Registry and
Health data, the Saskatchewan Health Plan Databases, the Scottish cancer registry
linked to the Tayside drug dispensing data, linked databases in the Nordic Coun-
tries of Europe: Norway, Sweden, Finland and Denmark, and the ECR-PHARMO
linkage in The Netherlands. Descriptives of included database linkages comprise
population size, generalizability of the population, year of first data availability,
vital status, contents of the cancer registry, contents of the administrative health-
care database, the possibility to select a cancer-free control cohort, and linkage to
other health care databases. CONCLUSIONS: Various valuable resources of infor-
mation are available to study the disease management of cancer, including treat-
ment patterns and outcomes assessments, creating new opportunities for post-
approval evaluation of anti-cancer drugs.
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OBJECTIVES: Cancer treatment models are often based on progression-free sur-
vival (PFS) and overall survival (OS) data. If the model objective requires extrapo-
lating results or exploring “what-if” scenarios, disease progression parameters are
calibrated so that the model replicates the PFS and OS data. Uncertainties in the
estimation of the Kaplan-Meier survival curves used as calibration targets, and in
the model calibration process itself, are not commonly incorporated into sensitiv-
ity analyses. The objective of this study was to demonstrate methods for incorpo-
rating these uncertainties into probabilistic sensitivity analyses (PSA) and to ex-
plore their implications. METHODS: We constructed hypothetical PFS and OS
survival (with censoring) for two treatments (TxA & TxB) and a corresponding
three-state Markov model (Non-progressed (NP), Progressed (P), Dead (D)). Health
states were assigned costs and utilities consistent with advanced cancer. Three
transition probabilities for each treatment (NP-P, NP-D, P-D) were calibrated
(using Excel Solver) to simultaneously fit (using mean squared deviation) the
PFS/OS curves. We performed three increasingly comprehensive PSAs using sec-
ond-order Monte Carlo simulation (SMCS): 1) conventional PSA including only
probability distributions of costs and utilities; 2) specifying beta distributions for
failure probabilities at each PFS/OS timepoint, simulatingmultiple replicates of the
PFS /OS data from these distributions, re-estimating and refitting the curves for
each replicate, and incorporating the resulting calibrated parameter sets into the
SMCS; and 3) incorporating different curve-fitting methods by varying Solver pa-
rameters (initial values, constraints, objective function). Uncertainty in cost-effec-
tiveness results was represented by cost-effectiveness acceptability curves (CEAC).
A178 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
